Ownership and insider activity for Akebia Therapeutics, Inc. (AKBA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials.
Price
| Price | $0.92 |
| Market Cap | $246M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-06 | Butler John P. | M-Exempt | 350,000 | $220K |
| 2026-08-06 | Butler John P. | M-Exempt | 350,000 | $220K |
| 2026-06-29 | Ostrowski Erik | S-Sale | 56,019 | $62K |
| 2026-06-17 | Wolf Myles | A-Award | 35,700 | |
| 2026-06-17 | Wolf Myles | A-Award | 53,600 | $55K |
| 2026-06-17 | Smith Cynthia | A-Award | 35,700 | |
| 2026-06-17 | Smith Cynthia | A-Award | 53,600 | $55K |
| 2026-06-17 | ROGERS MICHAEL W | A-Award | 35,700 | |
| 2026-06-17 | ROGERS MICHAEL W | A-Award | 53,600 | $55K |
| 2026-06-17 | FRIESON RON | A-Award | 35,700 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $187.3M | $70.2M | $104.6M | $147.7M | $229.1M | $149.8M | $90.5M | $42.9M | $51.9M | $184.8M |
| Short-term Investments | $73.0M | $247.6M | $217.0M | $245000 | $40.0M | 0 | 0 | 0 | 0 | 0 |
| Receivables | $33.8M | $34.2M | $16.7M | $38.9M | $28.6M | $51.6M | $40.3M | $39.3M | $34.4M | $47.0M |
| Inventory | 0 | 0 | $114.2M | $116.3M | $61.0M | $36.6M | $21.6M | $15.7M | $16.2M | $15.6M |
| Total Current Assets | $296.3M | $358.4M | $468.3M | $309.5M | $371.4M | $271.1M | $185.2M | $118.1M | $113.8M | $184.8M |
| Property, Plant & Equipment | $2.6M | $3.6M | $8.0M | $39.4M | $35.5M | $40.6M | $34.4M | $16.0M | $10.4M | 0 |
| Goodwill | 0 | 0 | $55.1M | $55.1M | $55.1M | $59.0M | $59.0M | $59.0M | $59.0M | $59.0M |
| Intangible Assets | 0 | 0 | $328.2M | $291.2M | $144.2M | $108.1M | $72.1M | $36.0M | 0 | 0 |
| Total Assets | $300.2M | $364.2M | $996.5M | $771.2M | $644.1M | $529.3M | $356.1M | $241.7M | $220.7M | $376.6M |
| Accounts Payable | $2.0M | $7.0M | $42.8M | $39.2M | $41.3M | $33.6M | $18.0M | $14.6M | $15.2M | $21.2M |
| Short-term Debt | 0 | 0 | $15.0M | $5.0M | $5.3M | $97.5M | $32.0M | $19.5M | $4.3M | $40.1M |
| Total Current Liabilities | $114.3M | $144.3M | $265.7M | $208.1M | $187.1M | $261.1M | $129.5M | $99.9M | $80.9M | $162.9M |
| Long-term Debt | 0 | 0 | 0 | $75.8M | $96.4M | $53.1M | $34.1M | $71.2M | $175.5M | $176.2M |
| Total Liabilities | $232.1M | $244.9M | $360.6M | $376.4M | $396.5M | $455.3M | $350.8M | $272.3M | $269.9M | $344.0M |
| Retained Earnings | -$297.1M | -$374.1M | -$514.4M | -$794.1M | -$1.18B | -$1.46B | -$1.56B | -$1.61B | -$1.68B | -$1.68B |
| Total Equity | $68.1M | $119.3M | $635.9M | $394.8M | $247.6M | $74.0M | $5.2M | -$30.6M | -$49.2M | $32.6M |
| Total Debt | 0 | 0 | $15.0M | $108.3M | $126.3M | $189.1M | $99.8M | $104.2M | $188.7M | $216.3M |
| Net Debt | -$260.3M | -$317.8M | -$306.6M | -$39.6M | -$142.8M | $39.3M | $9.3M | $61.3M | $136.9M | $31.5M |
| Working Capital | $182.1M | $214.0M | $202.6M | $101.4M | $184.3M | $10.1M | $55.6M | $18.3M | $32.9M | $21.9M |
Financial Health
| Debt / Equity | 2.16 |
| Current Ratio | 1.43 |
| Piotroski F-Score | 6 |
| Altman Z-Score | -4.63 |
Profitability
| Return on Equity | -93.74% |
| Return on Invested Capital | -7.08% |
| Return on Assets | -8.48% |
| Gross Margin | 79.48% |
| Operating Margin | -6.91% |
| Net Margin | -13.54% |
Related companies: CMPX · CRVS · FDMT · GOSS · KALV · OLMA · PRTA
Explore sector: Healthcare · Biotechnology
More sections of AKBA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks